Vaxil Bio Ltd.
VXLLF
$0.13
$0.122,021.31%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 136.50K | 140.50K | 119.90K | 59.50K | 43.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 143.00K | 147.00K | 138.40K | 92.70K | 75.50K |
| Operating Income | -143.00K | -147.00K | -138.40K | -92.70K | -75.50K |
| Income Before Tax | -74.40K | -131.10K | -125.30K | -90.50K | -75.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.07 | -0.13 | -0.13 | -0.09 | -0.08 |
| Earnings from Discontinued Operations | 4.30K | -5.10K | -5.10K | -5.10K | -5.10K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.00K | -136.20K | -130.40K | -95.60K | -80.60K |
| EBIT | -143.00K | -147.00K | -138.40K | -92.70K | -75.50K |
| EBITDA | -- | -- | -- | 23.20K | -1.00K |
| EPS Basic | -0.03 | -0.05 | -0.05 | -0.03 | -0.03 |
| Normalized Basic EPS | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 |
| EPS Diluted | -0.03 | -0.05 | -0.05 | -0.03 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 10.96M | 10.96M | 10.96M | 10.96M | 10.96M |
| Average Diluted Shares Outstanding | 10.96M | 10.96M | 10.96M | 10.96M | 10.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |